bioMérieux – Third-Quarter 2019 Business Review
22 Oktober, 2019
bioMérieux – First-Half 2019 Results
04 September, 2019
bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing
07 Februar, 2019
bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.
bioMérieux – First-Quarter 2018 Business Review
19 April, 2018
bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical
05 April, 2018
Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).